Digirad Receives FDA Nod for Cardiac SPECT/VCT Imager

 

March 26, 2009

March 26, 2009 - Digirad Corp. has received 510(k) clearance from the FDA to market and manufacture its Cardius X-ACT imaging system.

The Cardius X-ACT is a rapid cardiac SPECT/VCT imaging system that features a low-dose volume-computed tomography (VCT) attenuation correction system that reportedly significantly reduces artifacts in the images caused by overlying tissues increasing interpretive ease and accuracy. The revolutionary X-ACT approach takes advantage of the full 24-inch wide detector array eliminating truncation and generating high-precision transmission maps improving the overall quality of SPECT studies. The X-ACT attenuation correction system is designed to offer high accuracy, fast acquisition, low dose (5 uSv / study) and superb reliability. The system's high-speed triple-head solid-state design combined with nSPEED software allows the combined cardiac SPECT emission and transmission acquisitions to be performed in as little as five minutes.

Results of an extensive multi-center evaluation of the X-ACT technology will be presented during upcoming events including ACC in Orlando, ICNC 2009 in Barcelona, SNM 2009 in Toronto and ASNC 2009 in Minneapolis.

For more information: www.digirad.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.